Fecha de publicación
Nº de solicitud
|1.||WO||WO/2013/010553 - METHOD AND ANALYTICAL KIT FOR SIMULTANEOUS QUANTIFICATION OF B-COMPLEX VITAMIN CONTENT IN FOOD||24.01.2013||
|PCT/EE2012/000004||TALLINN UNIVERSITY OF TECHNOLOGY||HÄLVIN, Kristel|
The present invention relates to an analytical vitamin analysis kit, the method of its preparation, and the method of its application. The given analytical kit can be used for the simultaneous determination of the quantity of five B-complex vitamins (B l, B2, B3, B5 and B6) and individual vitamers in drugs, food, food- and bio-supplements, feed, and other biological samples using LC-MS isotope internal standard assay. The analytical kit is based on the use of sample vials containing lyophilized or dried isotope labelled internal standards of the B-complex vitamers with a mix of hydrolytic enzymes, used to convert vitamers and cofactors into the same chemical forms as the used isotope labelled internal standards, and for their following quantification by means of LC-MS or LC-MS/MS.
|2.||WO||WO/2012/159638 - NON-CYTOTOXIC ALPHA VIRAL CONSTRUCT, CELL LINE AND COMPOSITION AND A METHOD FOR THE ASSESSMENT OF THE EFFECT OF ANTIVIRAL AGENTS.||29.11.2012||
|PCT/EE2012/000003||TARTU ÜLIKOOL (UNIVERSITY OF TARTU)||LULLA, Aleksei|
The invention relates to the field of molecular biology and comprises constructs based on non-cytotoxic alphaviral mutants capable to replicate in a stable manner ant to be maintained in mammalian cells as well as cell lines capable to replicate said constructs in a stable manner. The invention provides new constructs based on an alphavirus, in particular Chikungunya virus, which are feasible to apply in the creation of expression systems and research for and analysis of antiviral substances due to their non-cytotoxic nature. The invention enables the assessment of drug candidates for the screening of anti-alphaviral substances. Also, the invention can be applied for expressing recombinant proteins in genetic engineering systems.
|3.||WO||WO/2012/126481 - ISOLATED MICROORGANISM STRAINS LACTOBACILLUS PLANTARUM MCC1 DSM 23881 AND LACTOBACILLUS GASSERI MCC2 DSM 23882 AND THEIR USE||27.09.2012||
|PCT/EE2012/000001||OÜ TERVISLIKU PIIMA BIOTEHNOLOOGIATE ARENDUSKESKUS||KULLISAAR, Tiiu|
The present invention relates to new microorganism strains L.plantarum MCCl DSM 23881 and L.gasseri MCC2 DSM 23882 and their use as antioxidant proteolytic ingredients for the production of food products and dietary supplements. Food products and dietary supplements containing L.plantarum MCCl and L.gasseri MCC2 are hypoallergenic, reduce milk allergy and lower urinary tract irritation symptoms accompanying benign prostatic hyperplasia and oxidative stress and inflammation associated with these.
|4.||WO||WO/2012/116708 - METHOD OF SHOOT-THROUGH GENERATION FOR MODIFIED SINE WAVE Z-SOURCE, QUASI-Z-SOURCE AND TRANS-Z-SOURCE INVERTERS||07.09.2012||
|PCT/EE2012/000002||TALLINN UNIVERSITY OF TECHNOLOGY||VINNIKOV, Dmitri|
This invention belongs into the field of power electronics and semiconductor converter control and pertains to the method of shoot-through generation for modified sine wave Z-source, quasi-Z-source and trans-Z-source inverters. The inverter can be controlled using either the modified sine wave pulse-width modulation or phase-shift modulation method. There are three methods for shoot-through generation in the case of modified sine wave control: by overlapping active states, during the freewheeling state and during the zero state.
|5.||WO||WO/2012/089221 - DEVICE AND METHOD FOR REAL-TIME MEASUREMENT OF PARAMETERS OF MECHANICAL STRESS STATE AND BIOMECHANICAL PROPERTIES OF SOFT BIOLOGICAL TISSUE||05.07.2012||
|PCT/EE2011/000009||MYOTON AS||VAIN, Arved|
A device and a method for simultaneous recording, in real time, of the parameters characterising the mechanical tension, elasticity, dynamical stiffness, creepability and mechanical stress of soft biological tissue is provided. By means of the myometer, a constant external pre-pressure is created, independently of the device's position, between the tissue and the testing end of the device. Next, the tissue is subjected to a short-term external dynamic influence. The mechanical change in the shape of the tissue and its mechanical response are registered as a graph of the tissue's oscillations. For calculating the parameters, the time span on the graph is used which involves the oscillation period from the beginning to the end of the effect on the tissue plus its subsequent first 1.5 self-oscillation period. Invention enables recording and data-processing to be carried out simultaneously as well as statistically significant estimates to be made in real time.
|6.||WO||WO/2012/089222 - A DURABLE HAEMOSTATIC SCAFFOLD||05.07.2012||
|PCT/EE2011/000011||TARTU ÜLIKOOL (UNIVERSITY OF TARTU)||JANMEY, Paul|
A haemostatic and adhesive durable scaffold useful for promoting wound healing is provided. A scaffold made of fibrinogen and chitosan is produced by electrospinning techniques, resulting in a material with enhanced endurance, applicable in various medical purposes including surgery, tissue regeneration, burns, injuries, etc. Scaffold is produced in the absence of biocatalysts, in particular thrombin.
|7.||WO||WO/2012/083972 - COMPOSITE OF POLYMERIC MATERIAL WITH MINERAL FILLERS||28.06.2012||
|PCT/EE2011/000010||TALLINN UNIVERSITY OF TECHNOLOGY||VIIKNA, Anti|
The present invention relates to the composite of a polymeric material with mineral fillers, which can be used for producing films, pipes and other products made by extrusion or injection moulding methods. The composite contains a homogeneous mixture of mineral and organic additives and thermoplastic polymers, whereas industrial waste, such as oil shale fly ash or clinker dust of cement industry or limestone mud or a mixture of the named substances, is used as mineral filler.
|8.||WO||WO/2012/010178 - PREFABRICATED WALL-MOUNTABLE COVER BOX||26.01.2012||
|PCT/EE2011/000001||BESTAIR LLC||KÕPPER, Ivo|
The prefabricated wall-mountable cover box consists of a prefabricated housing 1 and a flat roof 2, whereas the prefabricated housing 1 is composed of a rectangular latticed front panel 1.1, two latticed side panels 1.2 and two fixing bars 1.3, which form the rear wall of the housing 1; in order to give the roof 2 the necessary slope outwards away from the wall, the latticed side panels 1.2 are executed as trapezoids whereas the longer side edges 1.2.1 of the trapezoidal latticed side panels 1.2 are connected to the ends of the upper fixing bar 1.3 and the lower fixing bar 1.3 and the shorter side edges 1.2.2 to the side edges of the rectangular latticed front panel 1.1. The upper fixing bar 1.3 of the wall-mounted cover box is supported on U-form fixing elements 3.1 that have been fixed to two angle brackets 3 equipped with adjustment slots. The U-form fixing element 3.1 is equipped with a shank 3.1.1, a bolt 3.1.2 inserted through the shank 3.1.1 and the adjustment slot in the longer end of the angle bracket 3, due to which the U-form fixing element 3.1 can be moved towards or away from the wall. The width of the U-form fixing element 3.1 corresponds to the thickness of the cover box upper fixing bar 1.3 and its depth to 1/3...1/2 of the width of the upper fixing bar 1.3. In order to keep the lower part of the cover box at a prescribed distance from the wall, two long- thread bolts 4 are inserted through the cover box lower fixing bar 1.3 with their heads resting against the wall. The distance of the lower part of the cover box from the wall can be adjusted by fastening and loosening the nuts of the bolts 4. Due to the U-form fixing elements, which are fitted on angle brackets 3 and support the cover box upper fixing bar 1.3, the threaded bolts 4, which are inserted through the lower cover box fixing bar 1.3 and the heads of which are supported against the wall, the installation of the cover box on fixing elements and its removal from fixing elements is simple; it is easy to adjust the position of the cover box so that sufficient space is left between the housing 1 of the cover box and the wall in order to ensure free movement of air between the wall and the housing 1 of the cover box.
|9.||WO||WO/2012/000521 - A METHOD AND DEVICE FOR DETERMINING CONTENT OF THE MIDDLE AND PROTEIN BOUND UREMIC TOXINS IN A BIOLOGICAL FLUID||05.01.2012||
|PCT/EE2011/000008||TALLINN UNIVERSITY OF TECHNOLOGY||FRIDOLIN, Ivo|
This invention relates to a novel method and a device for determining middle and protein bound uremic toxins in the biological fluids. More specifically, the present invention relates to an optical method utilizing fluorescence, preferable fluorescence of the spent dialysate, and a specific model, including a unique set of optical spectral components at certain wavelengths, to determine, preferable on-line, the concentration of the middle and protein bound uremic toxins such as beta2-microglobulin (B2M), and indoxyl sulfate (IS).
|10.||WO||WO/2011/147425 - METHOD AND DEVICE FOR MEASURING AND MONITORING CONCENTRATION OF SUBSTANCES IN A BIOLOGICAL FLUID||01.12.2011||
|PCT/EE2011/000005||TALLINN UNIVERSITY OF TECHNOLOGY||FRIDOLIN, Ivo|
Method and device for monitoring removal of hardly or easily diffusible uremic retention solutes during dialysis and for measuring concentration of said substances in a biological fluid, and more specifically in the spent dialysate, for estimation of dialysis dose on dialysis patients. Measurements are performed optically utilizing spectrum of the biological fluid and a concentration calculation algorithm containing the transforming function, including a unique set of optical spectral components at certain wavelengths, to determine the concentration of the substances in specimens in-vitro or flowing fluids on-line. Method and device determines the concentration of the substances in-vitro or on-line utilizing a measuring cuvette suitable for specified measurements. This enables monitoring quantitatively concentrations of substances in a biological fluid and calculation of the dialysis dose for hardly or easily diffusible uremic retention solutes, suitable for automatic and time-efficient way to review the dialysis quality delivered to the end stage renal disease patients.